GILD 4Q19 HCV sales=$630M, -6.5% QoQ on a GAAP* basis. The 4Q19 HCV geographic breakdown was: US $337M; EU $151M; RoW $142M. Full-year 2019 HCV sales were $2.87B (consistent with the $2.7-2.9B guidance given in Feb 2019: #msg-146569713).
GILD’s worldwide HCV patient starts in 4Q19 (CC slide #38) increased to 45K from 42K in 3Q19 (an increase of 25K to 28K in the US), implying further price erosion in the market.
Market Data 
Markets 
AI
